In order to investigate safety and immunogenicity of SARS-CoV-2 vaccine third dose in people living with HIV (PLWH), we analyze anti-RBD, microneutralization assay and IFN-γ production in 216 PLWH on ART with advanced disease (CD4 count <200 cell/mm(3) and/or previous AIDS) receiving the third dose of a mRNA vaccine (BNT162b2 or mRNA-1273) after a median of 142 days from the second dose. Median age is 54 years, median CD4 nadir 45 cell/mm(3) (20-122), 93% HIV-RNA < 50 c/mL. In 68% of PLWH at least one side-effect, generally mild, is recorded. Humoral response after the third dose was strong and higher than that achieved with the second dose (>2 log(2) difference), especially when a heterologous combination with mRNA-1273 as third shot is used. In contrast, cell-mediated immunity remain stable. Our data support usefulness of third dose in PLWH currently receiving suppressive ART who presented with severe immune dysregulation.
Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV / Vergori, Alessandra; Cozzi Lepri, Alessandro; Cicalini, Stefania; Matusali, G; Bordoni, Veronica; Lanini, Simone; Meschi, Silvia; Iannazzo, Roberta; Mazzotta, Valentina; Colavita, Francesca; Mastrorosa, Ilaria; Cimini, Eleonora; Mariotti, Davide; De Pascale, Lydia; Marani, Alessandra; Gallì, Paola; Garbuglia, Annarosa; Castilletti, Concetta; Puro, Vincenzo; Agrati, Chiara; Girardi, Enrico; Vaia, Francesco; Antinori, Andrea. - In: NATURE COMMUNICATIONS. - ISSN 2041-1723. - 13:(2022). [10.1038/s41467-022-32263-7]
Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV
Matusali G;
2022
Abstract
In order to investigate safety and immunogenicity of SARS-CoV-2 vaccine third dose in people living with HIV (PLWH), we analyze anti-RBD, microneutralization assay and IFN-γ production in 216 PLWH on ART with advanced disease (CD4 count <200 cell/mm(3) and/or previous AIDS) receiving the third dose of a mRNA vaccine (BNT162b2 or mRNA-1273) after a median of 142 days from the second dose. Median age is 54 years, median CD4 nadir 45 cell/mm(3) (20-122), 93% HIV-RNA < 50 c/mL. In 68% of PLWH at least one side-effect, generally mild, is recorded. Humoral response after the third dose was strong and higher than that achieved with the second dose (>2 log(2) difference), especially when a heterologous combination with mRNA-1273 as third shot is used. In contrast, cell-mediated immunity remain stable. Our data support usefulness of third dose in PLWH currently receiving suppressive ART who presented with severe immune dysregulation.| File | Dimensione | Formato | |
|---|---|---|---|
|
Vergori_Immunogenicity_2022.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
1.55 MB
Formato
Adobe PDF
|
1.55 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
